Healthcare Professionals

Clinical Experience

Asclera® Injection was evaluated in a multicenter, randomized, double-blind, placebo and comparator-controlled trial (EASI-study) in patients with spider or reticular varicose veins. A total of 316 patients were treated with Asclera® (0.5% for spider veins [n=82], 1% for reticular veins [n=76], sodium tetradecyl sulfate [STS] 1% [n=105], or placebo [0.9% isotonic saline solution] [n= 53]) for either spider or reticular veins.

  • Patients received an intravenous injection in the first treatment session; repeat injections were given 3 and 6 weeks later if the previous injection was evaluated as unsuccessful (defined as 1, 2, or 3 on a 5-point scale)
  • Patients returned at 12 and 26 weeks after the last injection for final assessments. The primary effectiveness endpoint was improvement of veins judged by a blinded panel

Treatment Success1

  • 95% of patients treated with Asclera® showed good or complete treatment success as rated by physicians
  • Asclera® treatment results were statistically significant when compared to placebo (p<0.0001) for the primary efficacy criterion “improvement of veins”

success graph

*Treatment success was rated by a blinded panel on a 5-point scale (1 = worse than before, 2 = same as before, 3 = moderate improvement, 4 = good improvement, 5 = complete treatment success).

Overview and Application of Asclera